Last reviewed · How we verify
TIAGABINE HYDROCHLORIDE
TIAGABINE HYDROCHLORIDE is a drug. It is currently FDA-approved (first approved 1997).
At a glance
| Generic name | TIAGABINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
Common side effects
- Dizziness
- Somnolence
- Asthenia
- Nausea
- Abdominal Pain
- Vasodilation
- Diarrhea
- Vomiting
- Tremor
- Difficulty with Concentration/Attention
- Insomnia
- Ataxia
Key clinical trials
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- Treating Schizophrenia by Correcting Abnormal Brain Development (PHASE3)
- Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder (PHASE3)
- A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice (PHASE4)
- Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma (PHASE1, PHASE2)
- Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study. (PHASE4)
- Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence (PHASE1)
- Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIAGABINE HYDROCHLORIDE CI brief — competitive landscape report
- TIAGABINE HYDROCHLORIDE updates RSS · CI watch RSS
Frequently asked questions about TIAGABINE HYDROCHLORIDE
What is TIAGABINE HYDROCHLORIDE?
TIAGABINE HYDROCHLORIDE is a Small molecule drug.
When was TIAGABINE HYDROCHLORIDE approved?
TIAGABINE HYDROCHLORIDE was first approved on 1997.
What development phase is TIAGABINE HYDROCHLORIDE in?
TIAGABINE HYDROCHLORIDE is FDA-approved (marketed).
What are the side effects of TIAGABINE HYDROCHLORIDE?
Common side effects of TIAGABINE HYDROCHLORIDE include Dizziness, Somnolence, Asthenia, Nausea, Abdominal Pain, Vasodilation.